Top

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The National Institutes of Health is forecasting the continuation of the Blueprint Neurotherapeutics Network for Small Molecules (BPN-SM), a program aimed at advancing promising small-molecule therapeutics toward clinical testing. This initiative supports drug discovery and development within investigator laboratories by providing access to subject matter experts and contract research organizations specializing in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. The program is specifically limited to small molecules and excludes biologics to ensure appropriate regulatory and manufacturing alignment. The primary objective is to mitigate scientific and development risks to a level that encourages external partners to undertake late-stage development for patient delivery. Funding will be administered through a phased cooperative agreement mechanism, where continued support depends on meeting yearly milestones. This framework facilitates substantial collaboration between principal investigators and NIH program staff to manage the technical aspects of each project. While applications are not currently being solicited, this notice serves to allow potential applicants time to establish the necessary cross-disciplinary collaborations.

General Info

NIH seeks to advance investigator-led small-molecule therapeutics via collaborative, milestone-driven translational support.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedJul 7

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUSA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health

Office AddressUSA

Contacts

Blueprint Neurotherapeutics Team

contact@example.gov

Full Description

The NIH Blueprint for Neuroscience Research is interested in continuing to support the BluePrint Neurotherapeutics Network for Small Molecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development.

The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.